Bio-Rad Acquires Stilla Technologies
Bio-Rad Laboratories, a life science research and clinical diagnostics company, has completed the acquisition of Stilla Technologies, a developer of digital PCR (dPCR) systems. The transaction was finalized following a binding offer made earlier in the year and marks a significant expansion of Bio-Rad’s digital PCR capabilities.
Bio-Rad Laboratories has completed its acquisition of Stilla Technologies, a developer of next-generation digital PCR systems. The deal, recently finalized, follows a binding offer made earlier in the year and is expected to enhance Bio-Rad’s capabilities in the biotechnology sector.
Stilla Technologies, with operations in France and the US, specializes in digital PCR instruments, consumables, and assays used in applications such as oncology diagnostics, cell and gene therapy, and infectious disease testing. The acquisition is intended to complement Bio-Rad’s existing digital PCR portfolio and support its expansion in applied research and clinical diagnostics.
